The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review

Alessandra Bettiol, Elena Silvestri, Gerardo Di Scala, Amedeo Amedei, Matteo Becatti, Claudia Fiorillo, Giuseppe Lopalco, Carlo Salvarani, Luca Cantarini, Alessandra Soriano, Giacomo Emmi

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Behçet’s syndrome (BS) is a chronic (auto)-inflammatory disorder characterized by different clusters of symptoms, including mucocutaneous and ocular involvements. Interleukin-1 inhibitors anakinra (ANA), canakinumab (CAN), and gevokizumab (GEV) represent a promising therapeutic alternative in BS. To date, evidence on the use of ANA, CAN, and GEV is mainly based on small isolated studies or case series, and the real place of anti-IL1 agents in the treatment of BS is still unclear. We performed a systematic review of current evidence on the efficacy and safety of anti-IL1 agents in BS. The PubMed search yielded a total of 398 references, from which we retrieved 24 studies for inclusion (4 clinical trials, 6 observational studies, 14 case reports, case series or letters to the editor). Four studies evaluated the overall efficacy of IL-1 inhibitors, 15 studies focused on the specific efficacy of ANA, whereas efficacy of CAN and GEV was evaluated in 8 and 3 studies, respectively. Both ANA and CAN were associated with good control of mucocutaneous and ocular manifestations. ANA resulted effective also for osteoarticular manifestations. GEV was studied only for ocular manifestations, but gave contrasting results. Discordant evidence supports the use of ANA and CAN in pediatric setting and for first-line treatment of general BS manifestations. Most frequent side effects were local or diffuse cutaneous reactions and injection site reactions, particularly for ANA treatment. Blocking the IL-1 pathway could be an effective therapeutic strategy in particular BS involvements.

Original languageEnglish
JournalRheumatology International
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Interleukin 1 Receptor Antagonist Protein
Interleukin-1
Eye Manifestations
Therapeutics
PubMed
Observational Studies
canakinumab
Clinical Trials
Pediatrics
Safety
Skin
Injections
gevokizumab

Keywords

  • Anakinra
  • Behçet’s syndrome
  • Canakinumab
  • Gevokizumab
  • Interleukin-1

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome : a systematic review. / Bettiol, Alessandra; Silvestri, Elena; Di Scala, Gerardo; Amedei, Amedeo; Becatti, Matteo; Fiorillo, Claudia; Lopalco, Giuseppe; Salvarani, Carlo; Cantarini, Luca; Soriano, Alessandra; Emmi, Giacomo.

In: Rheumatology International, 01.01.2019.

Research output: Contribution to journalReview article

Bettiol, A, Silvestri, E, Di Scala, G, Amedei, A, Becatti, M, Fiorillo, C, Lopalco, G, Salvarani, C, Cantarini, L, Soriano, A & Emmi, G 2019, 'The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review', Rheumatology International. https://doi.org/10.1007/s00296-019-04259-y
Bettiol, Alessandra ; Silvestri, Elena ; Di Scala, Gerardo ; Amedei, Amedeo ; Becatti, Matteo ; Fiorillo, Claudia ; Lopalco, Giuseppe ; Salvarani, Carlo ; Cantarini, Luca ; Soriano, Alessandra ; Emmi, Giacomo. / The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome : a systematic review. In: Rheumatology International. 2019.
@article{c62abe084897455c99503f7005be6b61,
title = "The right place of interleukin-1 inhibitors in the treatment of Beh{\cc}et’s syndrome: a systematic review",
abstract = "Beh{\cc}et’s syndrome (BS) is a chronic (auto)-inflammatory disorder characterized by different clusters of symptoms, including mucocutaneous and ocular involvements. Interleukin-1 inhibitors anakinra (ANA), canakinumab (CAN), and gevokizumab (GEV) represent a promising therapeutic alternative in BS. To date, evidence on the use of ANA, CAN, and GEV is mainly based on small isolated studies or case series, and the real place of anti-IL1 agents in the treatment of BS is still unclear. We performed a systematic review of current evidence on the efficacy and safety of anti-IL1 agents in BS. The PubMed search yielded a total of 398 references, from which we retrieved 24 studies for inclusion (4 clinical trials, 6 observational studies, 14 case reports, case series or letters to the editor). Four studies evaluated the overall efficacy of IL-1 inhibitors, 15 studies focused on the specific efficacy of ANA, whereas efficacy of CAN and GEV was evaluated in 8 and 3 studies, respectively. Both ANA and CAN were associated with good control of mucocutaneous and ocular manifestations. ANA resulted effective also for osteoarticular manifestations. GEV was studied only for ocular manifestations, but gave contrasting results. Discordant evidence supports the use of ANA and CAN in pediatric setting and for first-line treatment of general BS manifestations. Most frequent side effects were local or diffuse cutaneous reactions and injection site reactions, particularly for ANA treatment. Blocking the IL-1 pathway could be an effective therapeutic strategy in particular BS involvements.",
keywords = "Anakinra, Beh{\cc}et’s syndrome, Canakinumab, Gevokizumab, Interleukin-1",
author = "Alessandra Bettiol and Elena Silvestri and {Di Scala}, Gerardo and Amedeo Amedei and Matteo Becatti and Claudia Fiorillo and Giuseppe Lopalco and Carlo Salvarani and Luca Cantarini and Alessandra Soriano and Giacomo Emmi",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00296-019-04259-y",
language = "English",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome

T2 - a systematic review

AU - Bettiol, Alessandra

AU - Silvestri, Elena

AU - Di Scala, Gerardo

AU - Amedei, Amedeo

AU - Becatti, Matteo

AU - Fiorillo, Claudia

AU - Lopalco, Giuseppe

AU - Salvarani, Carlo

AU - Cantarini, Luca

AU - Soriano, Alessandra

AU - Emmi, Giacomo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Behçet’s syndrome (BS) is a chronic (auto)-inflammatory disorder characterized by different clusters of symptoms, including mucocutaneous and ocular involvements. Interleukin-1 inhibitors anakinra (ANA), canakinumab (CAN), and gevokizumab (GEV) represent a promising therapeutic alternative in BS. To date, evidence on the use of ANA, CAN, and GEV is mainly based on small isolated studies or case series, and the real place of anti-IL1 agents in the treatment of BS is still unclear. We performed a systematic review of current evidence on the efficacy and safety of anti-IL1 agents in BS. The PubMed search yielded a total of 398 references, from which we retrieved 24 studies for inclusion (4 clinical trials, 6 observational studies, 14 case reports, case series or letters to the editor). Four studies evaluated the overall efficacy of IL-1 inhibitors, 15 studies focused on the specific efficacy of ANA, whereas efficacy of CAN and GEV was evaluated in 8 and 3 studies, respectively. Both ANA and CAN were associated with good control of mucocutaneous and ocular manifestations. ANA resulted effective also for osteoarticular manifestations. GEV was studied only for ocular manifestations, but gave contrasting results. Discordant evidence supports the use of ANA and CAN in pediatric setting and for first-line treatment of general BS manifestations. Most frequent side effects were local or diffuse cutaneous reactions and injection site reactions, particularly for ANA treatment. Blocking the IL-1 pathway could be an effective therapeutic strategy in particular BS involvements.

AB - Behçet’s syndrome (BS) is a chronic (auto)-inflammatory disorder characterized by different clusters of symptoms, including mucocutaneous and ocular involvements. Interleukin-1 inhibitors anakinra (ANA), canakinumab (CAN), and gevokizumab (GEV) represent a promising therapeutic alternative in BS. To date, evidence on the use of ANA, CAN, and GEV is mainly based on small isolated studies or case series, and the real place of anti-IL1 agents in the treatment of BS is still unclear. We performed a systematic review of current evidence on the efficacy and safety of anti-IL1 agents in BS. The PubMed search yielded a total of 398 references, from which we retrieved 24 studies for inclusion (4 clinical trials, 6 observational studies, 14 case reports, case series or letters to the editor). Four studies evaluated the overall efficacy of IL-1 inhibitors, 15 studies focused on the specific efficacy of ANA, whereas efficacy of CAN and GEV was evaluated in 8 and 3 studies, respectively. Both ANA and CAN were associated with good control of mucocutaneous and ocular manifestations. ANA resulted effective also for osteoarticular manifestations. GEV was studied only for ocular manifestations, but gave contrasting results. Discordant evidence supports the use of ANA and CAN in pediatric setting and for first-line treatment of general BS manifestations. Most frequent side effects were local or diffuse cutaneous reactions and injection site reactions, particularly for ANA treatment. Blocking the IL-1 pathway could be an effective therapeutic strategy in particular BS involvements.

KW - Anakinra

KW - Behçet’s syndrome

KW - Canakinumab

KW - Gevokizumab

KW - Interleukin-1

UR - http://www.scopus.com/inward/record.url?scp=85062014678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062014678&partnerID=8YFLogxK

U2 - 10.1007/s00296-019-04259-y

DO - 10.1007/s00296-019-04259-y

M3 - Review article

AN - SCOPUS:85062014678

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

ER -